乳毒素在额头纹治疗中的扩散特征和有效性
Young In Lee1,2, Nam Hao Chau3, Jemin Kim4
1Department of Dermatology & Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
The Journal of dermatological treatment
|October 6, 2025
概括
莱蒂博胺毒素A的扩散,有效性和安全性与其他用于治疗额头纹的A型肉毒神经毒素产品相比较. 这种新选择提供了一个潜在的更安全的替代方案,降低了扩散风险.
科学领域:
- 皮肤病学 皮肤病学
- 审美医学是一种美学医学.
- 神经学 神经学
背景情况:
- 面部纹通常用甲型肉毒神经毒素 (BoNT-A) 治疗.
- 过度的BoNT-A扩散会导致诸如肌肉衰弱之类的不良影响.
研究的目的:
- 为了比较letibotulinum毒素A与其他BoNT-A产品对额头纹的扩散,疗效和安全性.
主要方法:
- 一个双盲,随机,分脸试验涉及20名额头纹的参与者.
- 通过无水区域评估扩散;减少纹和安全是次要结果.
主要成果:
- 莱蒂博胺毒素A证明了可比的扩散模式和减少纹的有效性,以控制BoNT-A产品.
- 在治疗方法之间的初级或二级结果中没有发现显著差异.
结论:
- 莱蒂博胺毒素A是一种安全有效的纹治疗选择.
- 它可以将过度扩散和相关副作用的风险降到最低.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.1K
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
4.5K
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
4.5K
Centrally Acting Muscle Relaxants: Therapeutic Uses
1.2K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.2K
Skeletal Muscle Relaxants: Therapeutic Uses
891
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
891
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
894
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...
894


